BBP

Virtus LifeSci Biotech Products ETF
N/A

N/A
  • Overview
  • Efficiency
  • Tradability
  • Fit

BBP Fund Description

The Virtus LifeSci Biotech Products ETF tracks an index of biotechnology companies considered to be in the "product stage" by the index provider.

BBP Factset Analytics Insight

BBP offers a different approach to biotech investing by handpicking only firms that have attained FDA approval for their leading drug. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. BBP is likely to tilt smaller than our neutral cap-weighted benchmark because the fund equal-weights its holdings, and it dips into micro-caps as well. Unsurprisingly, risk is elevated compared to our benchmark. BBP can be tricky to trade at any scale. Onscreen volume is thin and spreads are large, while the small-cap basket may cause some liquidity problems for larger investors. It also charges a very high expense ratio for this segment. Overall, BBP provides an alternative but pricey take on the biotech segment.

BBP MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of November 21, 2017 the Virtus LifeSci Biotech Products ETF MSCI ESG Fund Quality Score is 4.27 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. BBP ranks in the 13th percentile within its peer group and in the 14th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:

BBP Top 10 Countries

BBP Top 10 Sectors

BBP Top 10 Holdings View All

BBP Summary Data

Virtus
12/17/14
Open-Ended Fund
0.79%
$36.84M
$170.11K
0.3%

BBP Portfolio Data

$19.21B
-24.5
7.27
0.00%
N/A
36

BBP Index Data

Equal
Proprietary
Thomson Reuters US Biotechnology & Medical Research

Related ETFs to BBP

XBI, FBT, CNCR, BBC
Total Return
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max

BBP Portfolio Management

0.79%
--
--
--

BBP Tax Exposures

20% / 39.6%
--
Qualified dividends
No

BBP Fund Structure

Open-Ended Fund
No
Yes
No Policy
N/A
N/A
High
Daily
Bats Book Viewer
TOP OF BOOK
SHARES/SIZEPRICE
ASKS----
----
----
----
----
BIDS----
----
----
----
----
LAST 10 TRADES
TIMEPRICESHARES
------
------
------
------
------
------
------
------
------
------
Bats BZX Real-time Quote - 23:59:59
Daily Spread
Premium/Discount
Volume

BBP Factset Analytics Block Liquidity

As of 11/22/17
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BBP. BBP is rated a 4 out of 5.

BBP Tradability

4,253
$170.11K
3,190
$123.71K
0.3%
$0.12
-0.03%
0.71% / -1.26%
None
100%
50,000
0.06
0.03%
0.27%
--
$38.73
4

BBP Geographic Exposure

BBPSegment Benchmark
99.48% 100.00%
0.52% --

BBPSegment Benchmark
99.48% 100.00%
0.52% --
99.48% / 0.52% 100.00% / 0.00%

BBP Performance Statistics

0.78
1.19
1.14
1.13
0.67%
Thomson Reuters US Biotechnology & Medical Research

BBP MSCI ESG Ratings

4.27 / 10
12.79
13.61
--
20.35%
26.59

BBP BENCHMARK COMPARISON

    BBP
    36 Holdings
    Segment Benchmark
    125 Constituents
    Shared Holdings
    29 (Count)
     
    26.67% (Weight)
BBPSegment Benchmark
52.32% 25.08%
29.63% 37.02%
16.09% 35.17%
1.95% 2.73%
146.49 -24.50
0.67% 0.14%
High Medium